fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.

Buprenorphine

All strengths: General benefit; same patient cost rules

Shared coverage and patient cost rules
StatusGeneral benefit
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.

Sublocade · DIN 02483084 · 100 mg/0.5 mL · injection solution- 0.5mL pre-filled syringe

General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
No interchangeable product listed in the Ontario extract
Sublocade · DIN 02483084 Manufacturer: Indivior UK Limited; listing date 2020-04-30 Health Canada: Marketed since 2020-02-03 · brand SUBLOCADE · ATC N07BC01 BUPRENORPHINE · form Solution (extended-release) · route Subcutaneous · ingredients BUPRENORPHINE 100 MG/0.5ML · company Indivior uk limited · schedule Narcotics (cdsa i)
Re-check Health Canada status and shortages (live) · Health Canada product record

Sublocade: Formulary list price $550.00 per unit (the source does not state the unit; exact figure $550.0000). What the ministry pays, not the patient.

Ministry pays: $550.0000 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02483084)

Source record
DIN 02483084: Sublocade Raw flags: sec3=Y Item: 280812024; group id 414; item number 1019; lccId None; manufacturer id IND Source form: Inj Sol- 0.5mL Pref Syr; strength: 100mg/0.5mL Recorded listing: General benefit Source prices (unrounded): $550.0000; ministry $550.0000 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02483084 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97348
Shortage status: resolved shortage (ended March 9, 2021); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02483084
Shortage record checked October 6, 2026

Sublocade · DIN 02483092 · 300 mg/1.5 mL · injection solution- 1.5mL pre-filled syringe

General benefitMarketed · checked November 17, 2026
Write on scriptno code needed
No interchangeable product listed in the Ontario extract
Sublocade · DIN 02483092 Manufacturer: Indivior UK Limited; listing date 2020-04-30 Health Canada: Marketed since 2020-02-03 · brand SUBLOCADE · ATC N07BC01 BUPRENORPHINE · form Solution (extended-release) · route Subcutaneous · ingredients BUPRENORPHINE 300 MG/1.5ML · company Indivior uk limited · schedule Narcotics (cdsa i)
Re-check Health Canada status and shortages (live) · Health Canada product record

Sublocade: Formulary list price $550.00 per unit (the source does not state the unit; exact figure $550.0000). What the ministry pays, not the patient.

Ministry pays: $550.0000 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02483092)

Source record
DIN 02483092: Sublocade Raw flags: sec3=Y Item: 280812025; group id 414; item number 1020; lccId None; manufacturer id IND Source form: Inj Sol- 1.5mL Pref Syr; strength: 300mg/1.5mL Recorded listing: General benefit Source prices (unrounded): $550.0000; ministry $550.0000 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02483092 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97349
Shortage status: resolved shortage (ended March 2, 2022); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02483092
Shortage record checked October 6, 2026

Other products in the same Health Canada class (N07BC): coverage varies; not interchangeable

  • Buprenorphine + naloxone (Suboxone): general benefit

Buprenorphine hydrochloride

All products: Limited Use (codes 578)

Probuphine · DIN 02474921 · 80 mg · Subdermal Implant-Kit Pk

Limited Use, Reason for Use code 578 required; Health Canada lists this DIN as Cancelled post market since 2023-06-30 — choose a marketed DIN from the same-category list.Discontinued June 30, 2023 · checked November 17, 2026
StatusLimited Use, Reason for Use code 578 required; Health Canada lists this DIN as Cancelled post market since 2023-06-30 — choose a marketed DIN from the same-category list.
Write on scriptReason for Use code 578 (criteria below); Health Canada lists this DIN as Cancelled post market since 2023-06-30 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 578
Reason for Use code 578 For the management of opioid use disorder in combination with counseling and psychosocial support in adult patients who meet the following criteria: - The patient is stabilized on a dose of no more than 8mg per day of sublingual buprenorphine for the preceding 90 days; AND - The patient is under the care of a health care provider with experience in the diagnosis and management of opioid use disorder and has been trained to implant and remove the buprenorphine subdermal implant. Recommended dose: Four 80mg implants inserted subdermally in the inner side of the upper arm for up to six months. The maximum quantity that can be claimed per patient is four (4) implant cycles (i.e. two (2) years of therapy). NOTE: The product monograph indicates that dosing beyond two (2) years cannot be recommended at this time. Probuphine subdermal implants are intended to be in place for six months of treatment. Probuphine implants are removed at the end of the six-month period. If continued treatment is desired, the implants should be replaced by new implants (implanted in the opposite arm) at the time of removal. Coverage limit: LU Authorization Period: 2 years
No interchangeable product listed in the Ontario extract
Probuphine · DIN 02474921 Manufacturer: Knight Therapeutics Inc.; listing date 2020-04-30 Health Canada: Cancelled post market since 2023-06-30 · brand PROBUPHINE · ATC N07BC01 BUPRENORPHINE · form Implant · route Subcutaneous · ingredients BUPRENORPHINE HYDROCHLORIDE 80 MG · company Knight therapeutics inc. · schedule Narcotics (cdsa i)
Re-check Health Canada status and shortages (live) · Health Canada product record

Probuphine: Formulary list price $1495.00 per unit (the source does not state the unit; exact figure $1495.0000). What the ministry pays, not the patient.

Ministry pays: $1495.0000 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02474921)

Source record
DIN 02474921: Probuphine Raw flags: sec12=Y, sec3=Y Item: 280812023; group id 416; item number 1027; lccId 00333; manufacturer id KNT Source form: Subdermal Implant-Kit Pk; strength: 80mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $1495.0000; ministry $1495.0000 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02474921 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96515
Shortage status: discontinued (July 3, 2023, reported by KNIGHT THERAPEUTICS INC.); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02474921
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since June 30, 2023 — choose a marketed DIN from the same-category list.

Other products in the same Health Canada class (N07BC): coverage varies; not interchangeable

  • Buprenorphine + naloxone (Suboxone): general benefit
Other drugs in the same formulary class (28:08:12 Opiate Partial Agonists) and how they are covered

Matched class: 28:08:12 Opiate Partial Agonists

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: BUPRENORPHINE & NALOXONE 28:08:12 Opiate Partial Agonists

BUPRENORPHINE & NALOXONE

· 10 products · General benefit · strengths: 2mg & 0.5mg, 8mg & 2mg, 4mg & 1mg, 12mg & 3mg · SL Tab, Soluble Film

BUTORPHANOL TARTRATE

· 2 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 10mg/mL · Nas Sp-2.5mL Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 28:08:12
Full class listing Related classes: 28:08:04 Nonsteroidal Anti-Inflammatory Agents, 28:08:08 Opiate Agonists, 28:08:92 Miscellaneous Analgesics and Antipyretics, 28:16:04 Antidepressants, 28:16:08 Tranquilizers, 28:16:12 Other Psychotropics, 28:36:08 Anticholinergic Agents, 28:36:20 Dopamine Receptor Agonists Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS SUBLOCADE (buprenorphine solution (extended-release) for injection) is indicated for the management of moderate to severe opioid use disorder in adult patients. SUBLOCADE should be used as part of a complete treatment plan that includes counselling and psychosocial support. SUBLOCADE must only be administered subcutaneously by a healthcare professional (see 4 DOSAGE AND ADMINISTRATION). 1.1 Pediatrics Pediatrics (˂18 years of age): No data are available in patients under 18 years of age. SUBLOCADE is not indicated in pediatric patients. 1.2 Geriatrics Geriatrics (≥ 65 years of age): There were no patients ≥ 65 years of age in the controlled clinical trial of SUBLOCADE. In general, drug use for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, respiratory and/or cardiac function, concomitant disease or other drug therapies. If the decision is made to prescribe SUBLOCADE to individuals 65 years of age or older, patients should be monitored for signs and symptoms of toxicity or overdose. https://pdf.hres.ca/dpd_pm/00082639.PDF PM date: NOV 20, 2018 Source product: SUBLOCADE; DIN 02483084; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
Product monograph unavailable: no marketed product found

Availability

Probuphine · DIN 02474921 Shortage status: discontinued (2023-07-03, reported by KNIGHT THERAPEUTICS INC.); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02474921

Check this DIN again